Clinical and biological significance of HLA-G expression in ovarian cancer

Seminars in Cancer Biology

Volumn 17, Issue 6, 2007, Pages 436-443

  Sheu, Jim Jinn Chyuan ^a,b,c   Shih, Ie Ming ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Clinical; HLA G; Immune; Lymphocytes; Ovarian cancer

Indexed keywords

B RAF KINASE; BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HLA G ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ANTIGEN BINDING; ANTIGEN EXPRESSION; BODY FLUID; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER SURVIVAL; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE LOCUS; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IMMUNOSURVEILLANCE; NATURAL KILLER CELL; OVARY CANCER; PROTEIN FUNCTION; REVIEW; ROC CURVE; UPREGULATION; WORLD HEALTH ORGANIZATION;

FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNOLOGIC SURVEILLANCE; OVARIAN NEOPLASMS; TUMOR ESCAPE; TUMOR MARKERS, BIOLOGICAL;

EID: 35748984924     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcancer.2007.06.012     Document Type: Review

References (67)

1. Greaves M. Darwinian medicine: a case for cancer. Nat Rev Cancer 7 (2007) 213-221
2. Hayakawa S. No cancer in cancers: evolutionary trade-off between successful viviparity and tumor escape from the adaptive immune system. Med Hypotheses 66 (2006) 888-897
3. Kovats S., Main E.K., Librach C., Stubblebine M., Fisher S.J., and DeMars R. A class I antigen, HLA-G, expressed in human trophoblasts. Science 248 (1990) 220-223
4. Shih Ie M. Application of human leukocyte antigen-g expression in the diagnosis of human cancer. Hum Immunol 68 (2007) 272-276
5. Tavassoli F., and Devilee P. Tumors of the ovary and peritoneum. World Health Organization classification of tumors-pathology and genetics of tumors of the breast and female genital organs (2003), IARC Press, Lyon, France pp. 114-6
6. Berek J.S., and Martinez-Maza O. Molecular and biologic factors in the pathogenesis of ovarian cancer. J Reprod Med 39 (1994) 241-248
7. DuBeau C.E. Urinary incontinence management: new questions from old assumptions. J Am Geriatr Soc 49 (2001) 829-830
8. Shih Ie M., and Kurman R.J. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164 (2004) 1511-1518
9. Shih Ie M., and Kurman R.J. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res 11 (2005) 7273-7279
10. Salani R, Kurman RJ, Giuntoli IR, Gardner GJ, Bristow RE, Wang TL, et al. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a much higher mutation rate than previously reported and does not correlate with drug resistance. Int J Gynecol Cancer (in press).
11. Crisa L., McMaster M.T., Ishii J.K., Fisher S.J., and Salomon D.R. Identification of a thymic epithelial cell subset sharing expression of the class Ib HLA-G molecule with fetal trophoblasts. J Exp Med 186 (1997) 289-298
12. Rouas-Freiss N., Moreau P., Ferrone S., and Carosella E.D. HLA-G proteins in cancer: do they provide tumor cells with an escape mechanism?. Cancer Res 65 (2005) 10139-10144
13. Kleinberg L., Florenes V.A., Skrede M., Dong H.P., Nielsen S., McMaster M.T., et al. Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma. Virchows Arch 449 (2006) 31-39
14. Hansel D.E., Rahman A., Wilentz R.E., Shih Ie M., McMaster M.T., Yeo C.J., et al. HLA-G upregulation in pre-malignant and malignant lesions of the gastrointestinal tract. Int J Gastrointest Cancer 35 (2005) 15-23
15. Singer G., Kurman R.J., McMaster M., and Shih I.-M. HLA-G immunoreactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis. Am J Surg Pathol 26 (2002) 914-920
16. Singer G., Rebmann V., Chen Y.-C., Liu H.-T., Ali S.Z., Reinsberg J., et al. HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res 9 (2003) 4460-4464
17. Bukur J., Rebmann V., Grosse-Wilde H., Luboldt H., Ruebben H., Drexler I., et al. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res 63 (2003) 4107-4111
18. Urosevic M., Kurrer M.O., Kamarashev J., Mueller B., Weder W., Burg G., et al. Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production. Am J Pathol 159 (2001) 817-824
19. Wiendl H., Mitsdoerffer M., and Weller M. Hide-and-seek in the brain: a role for HLA-G mediating immune privilege for glioma cells. Semin Cancer Biol 13 (2003) 343-351
20. El-Chennawi F.A., Auf F.A., El-Diasty A.M., El-Daim M.A., El-Sherbiny S.M., Ali A., et al. Expression of HLA-G in cancer bladder. Egypt J Immunol 12 (2005) 57-64
21. Ye S.R., Yang H., Li K., Dong D.D., Lin X.M., and Yie S.M. Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol 20 (2007) 375-383
22. Amiot L., Le Friec G., Sebti Y., Drenou B., Pangault C., Guilloux V., et al. HLA-G and lymphoproliferative disorders. Semin Cancer Biol 13 (2003) 379-385
23. Rebmann V., Pfeiffer K., Passler M., Ferrone S., Maier S., Weiss E., et al. Detection of soluble HLA-G molecules in plasma and amniotic fluid. Tissue Antigens 53 (1999) 14-22
24. Rebmann V., van der Ven K., Passler M., Pfeiffer K., Krebs D., and Grosse-Wilde H. Association of soluble HLA-G plasma levels with HLA-G alleles. Tissue Antigens 57 (2001) 15-21
25. Rebmann V., Regel J., Stolke D., and Grosse-Wilde H. Secretion of sHLA-G molecules in malignancies. Semin Cancer Biol 13 (2003) 371-377
26. Gros F., Sebti Y., de Guibert S., Branger B., Bernard M., Fauchet R., et al. Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages. Neoplasia 8 (2006) 223-230
27. Nakayama K., Nakayama N., Jinawath N., Salani R., Kurman R.J., Shih Ie M., et al. Amplicon profiles in ovarian serous carcinomas. Int J Cancer 120 (2007) 2613-2617
28. Mouillot G., Marcou C., Zidi I., Guillard C., Sangrouber D., Carosella E.D., et al. Hypoxia modulates HLA-G gene expression in tumor cells. Hum Immunol 68 (2007) 277-285
29. Chang C.C., and Ferrone S. HLA-G in melanoma: can the current controversies be solved?. Semin Cancer Biol 13 (2003) 361-369
30. Ibrahim E.C., Morange M., Dausset J., Carosella E.D., and Paul P. Heat shock and arsenite induce expression of the nonclassical class I histocompatibility HLA-G gene in tumor cell lines. Cell Stress Chaperones 5 (2000) 207-218
31. Moreau P., Faure O., Lefebvre S., Ibrahim E.C., O'Brien M., Gourand L., et al. Glucocorticoid hormones upregulate levels of HLA-G transcripts in trophoblasts. Transplant Proc 33 (2001) 2277-2280
32. Yie S.M., Li L.H., Li G.M., Xiao R., and Librach C.L. Progesterone enhances HLA-G gene expression in JEG-3 choriocarcinoma cells and human cytotrophoblasts in vitro. Hum Reprod 21 (2006) 46-51
33. Moreau P., Adrian-Cabestre F., Menier C., Guiard V., Gourand L., Dausset J., et al. IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int Immunol 11 (1999) 803-811
34. Urosevic M., Willers J., Mueller B., Kempf W., Burg G., and Dummer R. HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood 99 (2002) 609-617
35. Wagner S.N., Rebmann V., Willers C.P., Grosse-Wilde H., and Goos M. Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma. Lancet 356 (2000) 220-221
36. Lefebvre S., Berrih-Aknin S., Adrian F., Moreau P., Poea S., Gourand L., et al. A specific interferon (IFN)-stimulated response element of the distal HLA-G promoter binds IFN-regulatory factor 1 and mediates enhancement of this nonclassical class I gene by IFN-beta. J Biol Chem 276 (2001) 6133-6139
37. Ugurel S., Rebmann V., Ferrone S., Tilgen W., Grosse-Wilde H., and Reinhold U. Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer 92 (2001) 369-376
38. Rouas-Freiss N., Moreau P., Menier C., and Carosella E.D. HLA-G in cancer: a way to turn off the immune system. Semin Cancer Biol 13 (2003) 325-326
39. Moreau P., Mouillot G., Rousseau P., Marcou C., Dausset J., and Carosella E.D. HLA-G gene repression is reversed by demethylation. Proc Natl Acad Sci USA 100 (2003) 1191-1196
40. Boucraut J., Guillaudeux T., Alizadeh M., Boretto J., Chimini G., Malecaze F., et al. HLA-E is the only class I gene that escapes CpG methylation and is transcriptionally active in the trophoblast-derived human cell line JAR. Immunogenetics 38 (1993) 117-130
41. Mouillot G., Marcou C., Rousseau P., Rouas-Freiss N., Carosella E.D., and Moreau P. HLA-G gene activation in tumor cells involves cis-acting epigenetic changes. Int J Cancer 113 (2005) 928-936
42. Chang C.C., Murphy S.P., and Ferrone S. Differential in vivo and in vitro HLA-G expression in melanoma cells: potential mechanisms. Hum Immunol 64 (2003) 1057-1063
43. Ibrahim E.C., Guerra N., Lacombe M.J., Angevin E., Chouaib S., Carosella E.D., et al. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma. Cancer Res 61 (2001) 6838-6845
44. Onno M., Le Friec G., Pangault C., Amiot L., Guilloux V., Drenou B., et al. Modulation of HLA-G antigens expression in myelomonocytic cells. Hum Immunol 61 (2000) 1086-1094
45. Khong H.T., and Restifo N.P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 3 (2002) 999-1005
46. Mocellin S., Wang E., and Marincola F.M. Cytokines and immune response in the tumor microenvironment. J Immunother 24 (2001) 392-407
47. Urosevic M., and Dummer R. HLA-G and IL-10 expression in human cancer-different stories with the same message. Semin Cancer Biol 13 (2003) 337-342
48. Dummer R., Willers J., Kamarashev J., Urosevic M., Dobbeling U., and Burg G. Pathogenesis of cutaneous lymphomas. Semin Cutan Med Surg 19 (2000) 78-86
49. Asadullah K., Docke W.D., Volk H.D., and Sterry W. Cytokines and cutaneous T-cell lymphomas. Exp Dermatol 7 (1998) 314-320
50. LeMaoult J., Le Discorde M., Rouas-Freiss N., Moreau P., Menier C., McCluskey J., et al. Biology and functions of human leukocyte antigen-G in health and sickness. Tissue Antigens 62 (2003) 273-284
51. Rizzo R., Melchiorri L., Stignani M., and Baricordi O.R. HLA-G expression is a fundamental prerequisite to pregnancy. Hum Immunol 68 (2007) 244-250
52. Sher G., Keskintepe L., Fisch J.D., Acacio B.A., Ahlering P., Batzofin J., et al. Soluble human leukocyte antigen G expression in phase I culture media at 46 h after fertilization predicts pregnancy and implantation from day 3 embryo transfer. Fertil Steril 83 (2005) 1410-1413
53. Noci I., Fuzzi B., Rizzo R., Melchiorri L., Criscuoli L., Dabizzi S., et al. Embryonic soluble HLA-G as a marker of developmental potential in embryos. Hum Reprod 20 (2005) 138-146
54. Rebmann V., Switala M., Eue I., Schwahn E., Merzenich M., and Grosse-Wilde H. Rapid evaluation of soluble HLA-G levels in supernatants of in vitro fertilized embryos. Hum Immunol 68 (2007) 251-258
55. Jurisicova A., Casper R.F., MacLusky N.J., Mills G.B., and Librach C.L. HLA-G expression during preimplantation human embryo development. Proc Natl Acad Sci USA 93 (1996) 161-165
56. Pfeiffer K.A., Fimmers R., Engels G., van der Ven H., and van der Ven K. The HLA-G genotype is potentially associated with idiopathic recurrent spontaneous abortion. Mol Hum Reprod 7 (2001) 373-378
57. Aldrich C.L., Stephenson M.D., Karrison T., Odem R.R., Branch D.W., Scott J.R., et al. HLA-G genotypes and pregnancy outcome in couples with unexplained recurrent miscarriage. Mol Hum Reprod 7 (2001) 1167-1172
58. Creput C., Durrbach A., Menier C., Guettier C., Samuel D., Dausset J., et al. Human leukocyte antigen-G (HLA-G) expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation. J Hepatol 39 (2003) 587-594
59. Rajagopalan S., and Long E.O. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med 189 (1999) 1093-1100
60. Ponte M., Cantoni C., Biassoni R., Tradori-Cappai A., Bentivoglio G., Vitale C., et al. Inhibitory receptors sensing HLA-G1 molecules in pregnancy: decidua-associated natural killer cells express LIR-1 and CD94/NKG2A and acquire p49, an HLA-G1-specific receptor. Proc Natl Acad Sci USA 96 (1999) 5674-5679
61. Cosman D., Fanger N., Borges L., Kubin M., Chin W., Peterson L., et al. A novel immunoglobulin superfamily receptor for cellular and viral MHC class I molecules. Immunity 7 (1997) 273-282
62. Colonna M., Navarro F., Bellon T., Llano M., Garcia P., Samaridis J., et al. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 186 (1997) 1809-1818
63. Rajagopalan S., Fu J., and Long E.O. Cutting edge: induction of IFN-gamma production but not cytotoxicity by the killer cell Ig-like receptor KIR2DL4 (CD158d) in resting NK cells. J Immunol 167 (2001) 1877-1881
64. Clements C.S., Kjer-Nielsen L., McCluskey J., and Rossjohn J. Structural studies on HLA-G: implications for ligand and receptor binding. Hum Immunol 68 (2007) 220-226
65. LeMaoult J., Zafaranloo K., Le Danff C., and Carosella E.D. HLA-G up-regulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J 19 (2005) 662-664
66. Davidson B., Elstrand M.B., McMaster M.T., Berner A., Kurman R.J., Risberg B., et al. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecol Oncol 96 (2005) 42-47
67. Naji A., Durrbach A., Carosella E.D., and Rouas-Freiss N. Soluble HLA-G and HLA-G1 expressing antigen-presenting cells inhibit T-cell alloproliferation through ILT-2/ILT-4/FasL-mediated pathways. Hum Immunol 68 (2007) 233-239